The pharmacological case for cannabigerol

Rahul Nachnani, Wesley M. Raup-Konsavage, Kent E. Vrana

Research output: Contribution to journalReview articlepeer-review

Abstract

Medical cannabis and individual cannabinoids, such as Δ9- tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD), are receiving growing attention in both the media and the scientific literature. The Cannabis plant, however, produces over 100 different cannabinoids, and cannabigerol (CBG) serves as the precursor molecule for the most abundant phytocannabinoids. CBG exhibits affinity and activity characteristics between Δ9-THC and CBD at the cannabinoid receptors but appears to be unique in its interactions with α-2 adrenoceptors and 5-hydroxytryptamine (5-HT1A). Studies indicate that CBG may have therapeutic potential in treating neurologic disorders (e.g., Huntington disease, Parkinson disease, and multiple sclerosis) and inflammatory bowel disease, as well as having antibacterial activity. There is growing interest in the commercial use of this unregulated phytocannabinoid. This review focuses on the unique pharmacology of CBG, our current knowledge of its possible therapeutic utility, and its potential toxicological hazards.

Original languageEnglish (US)
Pages (from-to)204-212
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume376
Issue number2
DOIs
StatePublished - Feb 1 2021

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology

Fingerprint Dive into the research topics of 'The pharmacological case for cannabigerol'. Together they form a unique fingerprint.

Cite this